GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biotech company specializing in the treatment of epilepsy and other neurological disorders. Its stock price is highly volatile, driven by news of clinical trials of its drugs, which investors are pinning high hopes on.
Share prices of companies in the market segment - Neuro
Xenon is a biotech company specializing in epilepsy treatment. We classify it in the pharmaceuticals (neurology) sector, and the chart below reflects general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of neurological disorders, particularly epilepsy. Its focus on innovation makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Xenon compares to it.
Change in the price of a company, segment, and market as a whole per day
XENE - Daily change in the company's share price Xenon Pharmaceuticals
In the world of biotech, every day is a wait for a breakthrough. Change_co for Xenon Pharma measures the sector's inherent volatility, reflecting reactions to clinical trial news. This metric, while unspectacular in itself, is an indispensable component for building complex risk and prospect assessment models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Xenon Pharmaceuticals Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with XENE, which focuses on epilepsy treatment, helps to assess it as a high-risk, data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Xenon is a biopharmaceutical company specializing in drugs for the treatment of epilepsy and other neurological disorders. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Xenon Pharmaceuticals
Xenon is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Annual dynamics of market capitalization of the market segment - Neuro
Xenon Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing drugs for the treatment of epilepsy and other neurological disorders. Its stock performance is entirely dependent on clinical trial results, reflecting its high risk and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xenon Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Xenon Pharmaceuticals
The price of Xenon, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for the treatment of epilepsy and other neurological diseases, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Neuro
Xenon Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of innovative treatments for epilepsy and other neurological disorders. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how promising clinical data on its leading drugs influences the company's perception in the scientific and investment communities.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xenon Pharmaceuticals is a biopharmaceutical company focused on epilepsy treatment. Shares of such companies often rise or fall by tens of percent after the publication of research data. The chart below shows how Xenon's performance has been out of sync with the market, moving in sync with scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Xenon Pharmaceuticals
Xenon Pharmaceuticals, a company focused on treating neurological disorders, is extremely news-sensitive. Weekly price movements reflect the release of clinical trial data, regulatory decisions, and progress in epilepsy drug development. The chart below illustrates how short-term events in biotech can trigger sharp fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
How does Xenon Pharmaceuticals' performance compare to the broader biotech sector? This chart compares the company's weekly share price movements, driven by news about its epilepsy treatment, with the overall trend. This helps us understand whether the stock's movement is the result of a unique scientific event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Xenon Pharmaceuticals develops drugs to treat epilepsy and other neurological disorders. This chart compares its weekly performance with the market. It clearly demonstrates how the biotech company's shares can rise or fall sharply on clinical trial news, ignoring the S&P 500.
Market capitalization of the company, segment and market as a whole
XENE - Market capitalization of the company Xenon Pharmaceuticals
The Xenon Pharmaceuticals valuation chart reflects investor expectations for its drugs for the treatment of epilepsy and other neurological disorders. This biotech company's market cap is heavily dependent on clinical trial results. Its share price dynamics mirror the market's reaction to each piece of news about its scientific developments.
XENE - Share of the company's market capitalization Xenon Pharmaceuticals within the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders, particularly epilepsy. Its share of its sector market capitalization reflects the significant potential of its drug candidates. The chart shows how investor expectations for clinical trial results shape its market value and industry weight.
Market capitalization of the market segment - Neuro
This chart shows the total value of biotech companies developing drugs to treat neurological diseases. Xenon Pharmaceuticals is a leader in ion channel research. The dynamics on the chart reflect the hopes and risks associated with the search for new treatments for epilepsy and depression.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market valuation of hope for patients with neurological diseases. Xenon Pharmaceuticals' market cap reflects investors' faith in its scientific platform for treating epilepsy. The line illustrates how focused biotech research can create enormous value and carve out a niche in global medicine.
Book value capitalization of the company, segment and market as a whole
XENE - Book value capitalization of the company Xenon Pharmaceuticals
Xenon Pharmaceuticals' book value represents its scientific capital. The chart below reflects the value of its intellectual property—patents for drugs used to treat epilepsy and other neurological disorders. A rising line indicates progress in clinical research, which forms the company's primary asset.
XENE - Share of the company's book capitalization Xenon Pharmaceuticals within the market segment - Neuro
For Xenon Pharmaceuticals, tangible assets aren't production lines, but cutting-edge laboratories and scientific equipment for developing drugs for neurological disorders. The chart shows the company's share of the physical infrastructure in its niche, reflecting the capital intensity of its research activities.
Market segment balance sheet capitalization - Neuro
Xenon Pharmaceuticals is a biotech company whose value is created in laboratories developing drugs for the treatment of epilepsy. It's a "light" model, based on science. The chart below shows how much the pharmaceutical industry as a whole relies on tangible assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Xenon Pharmaceuticals' balance sheet is capital focused on studying ion channels to develop new drugs for epilepsy and depression. The book value chart shows the amount of resources devoted to this complex and promising area of neuroscience, reflecting its scientific weight in the industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Xenon Pharmaceuticals
Xenon Pharmaceuticals specializes in developing drugs for epilepsy and other neurological disorders. The company has no significant tangible assets. Its market capitalization is an estimate of its scientific platform and the potential of its drug candidates. The chart reflects investor expectations for the creation of a new standard of treatment in neurology.
Market to book capitalization ratio in a market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological diseases, particularly epilepsy. Its value depends almost entirely on the success of clinical trials. This chart shows the enormous premium investors are pricing in in anticipation of breakthrough drugs.
Market to book capitalization ratio for the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological diseases, particularly epilepsy. This chart illustrates how the market values a potential medical breakthrough. Xenon's market value is based not on its current assets, but on investors' expectations for the success of its clinical programs, which creates a significant premium to its book value.
Debts of the company, segment and market as a whole
XENE - Company debts Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for neurological disorders such as epilepsy. Lengthy and expensive clinical trials require a constant influx of capital. This chart shows how the company utilizes financial resources to bring its promising drugs to patients.
Market segment debts - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurological disorders, particularly epilepsy. The drug development process is long and expensive. This chart provides insight into the financial norms of the pharmaceutical industry, where clinical-stage companies raise significant capital to conduct research and testing.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for neurological disorders such as epilepsy. Clinical trials in this area are lengthy and expensive. This chart shows how reliant the company is on external capital, including debt, to fund its research pipeline.
Market segment debt to market segment book capitalization - Neuro
Xenon Pharmaceuticals specializes in developing treatments for neurological disorders such as epilepsy. This requires long-term, high-risk investments in science. This chart compares the company's debt raised for R&D to the total market capitalization of the entire neurological pharmaceutical sector. It reflects the scale of its scientific ambitions.
Debt to book value of all companies in the market
Xenon Pharmaceuticals develops drugs to treat neurological diseases. This chart compares the company's debt to the total book value of the entire economy. It shows how the innovative biotech company's financial needs compare to the overall market conditions that provide the capital for its expensive research.
P/E of the company, segment and market as a whole
P/E - Xenon Pharmaceuticals
This chart for Xenon Pharmaceuticals, a biopharmaceutical company specializing in neuroscience, should be viewed in the context of the industry. Its value is determined not by current profits, but by the potential of its drugs for the treatment of epilepsy and other disorders. This metric reflects investors' faith in scientific developments and future commercial success.
P/E of the market segment - Neuro
This metric represents the average valuation for the biotech sector in which Xenon Pharmaceuticals operates. In this industry, which is full of research-stage companies, the average earnings valuation is often uninformative. However, it reflects the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding the company's value.
P/E of the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological disorders, particularly epilepsy. The company strives to offer new solutions for patients. This risk appetite chart helps understand how investors evaluate the potential for breakthroughs in brain disease treatments.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological disorders, particularly epilepsy. This chart reflects market expectations regarding the success of clinical trials and the future commercial potential of its drugs. It is an estimate of the likelihood of a breakthrough in the treatment of brain diseases.
%20P%2FE%20Xenon%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Xenon-Pharmaceuticals&v=1772653983132 "Chart of the company's future (projected) P/E Xenon Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of innovative treatments for neurological disorders, primarily epilepsy, by targeting ion channels in the brain. This chart shows overall market sentiment regarding the biotech sector, helping to assess Xenon's potential relative to expectations across the neuroscience industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772653983142 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Xenon Pharmaceuticals is a biotech company specializing in developing drugs for the treatment of epilepsy and other neurological disorders. Its valuation is entirely dependent on the results of clinical trials. Compared to general market forecasts, Xenon is a story of scientific discovery and solutions for complex diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772653983186 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders, particularly epilepsy. Being in the clinical stage, the company incurs significant research expenses. This chart reflects the company's investment in the development of potentially revolutionary drugs that could generate significant future profits.
Profit of companies in the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases, particularly epilepsy. This chart shows the overall profitability of the neurological segment. While in clinical trials, Xenon contributes to overall profitability through its R&D expenditures. Its success could lead to treatment breakthroughs and growth for the entire sector.
Overall market profit
Xenon Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for neurological diseases such as epilepsy. Its success depends on clinical trial results and scientific breakthroughs. This chart illustrates the overall economic trends that inform Xenon's work to develop innovative drugs whose value is independent of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders, particularly epilepsy. This chart reflects analysts' expectations for future earnings, which are entirely dependent on clinical trial results and potential approval of its drugs. It is an indicator of market confidence in the company's scientific platform.
%20profit%20of%20the%20company%20Xenon%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Xenon-Pharmaceuticals&v=1772653983208 "Graph of future (projected) profit of the company Xenon Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurological disorders, particularly epilepsy. This chart shows revenue projections for the neurology segment. It reflects expectations for clinical trials and potential approval of new drugs that could change patients' lives.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772653983314 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company focused on treating neurological diseases such as epilepsy. Its success is driven by scientific breakthroughs. However, the overall profit outlook reflected here shapes the investment climate. Market optimism facilitates raising the significant capital Xenon needs to conduct costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772653983337 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders, particularly epilepsy. While P/S is not a key metric at the clinical stage, it will become critical after a product's launch to assess its commercial potential.
P/S market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological disorders, particularly epilepsy. Being in the clinical stage, its valuation is based on future potential. This chart shows the premium investors place on its research compared to other companies in the neuroscience sector.
P/S of the market as a whole
Xenon Pharmaceuticals is a biotech company specializing in the treatment of neurological disorders, particularly epilepsy. The company's revenue depends on the success of its clinical programs and future drug sales. This revenue estimate chart provides a backdrop to the market's appreciation for the potential of companies working to address complex brain problems.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological diseases, particularly epilepsy. Its value is determined by the potential of its leading drugs. This chart reflects investor expectations for future sales, which could reach billions of dollars if clinical trials are successful.
%20P%2FS%20Xenon%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Xenon-Pharmaceuticals&v=1772653983438 "The graph of the company's future (projected) P/S Xenon Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological disorders, particularly epilepsy. This chart compares market expectations for the future commercial potential of its drugs with those of other companies in the neuroscience sector, reflecting investor confidence in its scientific developments and clinical data.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772653983442 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders, particularly epilepsy. Its developments have the potential to radically change the lives of patients. This chart shows revenue expectations for the entire market, and Xenon demonstrates how investor faith in scientific progress in medicine shapes long-term growth expectations, despite the risks.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772653983466 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological disorders, primarily epilepsy. In this chart, its revenue likely consists of collaboration fees rather than product sales, as its drugs are in clinical trials. Growth will depend on their success and commercialization.
Sales of companies in the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders, particularly epilepsy. This chart shows its revenue sources, which currently consist primarily of payments from major partners like Neurocrine Biosciences, confirming the value of its developments.
Overall market sales
Xenon Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for neurological diseases such as epilepsy. Its value is determined by progress in clinical trials. This overall market performance chart is not directly related to scientific breakthroughs, which are the sole driver of Xenon's success.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of epilepsy and other neurological disorders. Its revenue forecast is dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its innovative approaches to treating brain diseases.
%20sales%20of%20the%20company%20Xenon%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Xenon-Pharmaceuticals&v=1772653983674 "Schedule of future (projected) sales of the company Xenon Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for neurological diseases, particularly epilepsy. This chart shows projected revenues for the entire neurology segment. It allows one to assess whether analysts see growth potential in this market, which is crucial for the future commercial success of Xenon's drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772653983693 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases, particularly epilepsy. The company's success depends on the results of clinical trials. However, the overall market environment, shown in the chart, influences investor sentiment and their willingness to fund long-term and risky R&D projects in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772653983729 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders such as epilepsy. This chart reflects the active clinical development stage. It doesn't show revenue, but rather the amount of research investment, the success of which determines the company's future commercial profitability.
Market segment marginality - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for epilepsy and other neurological disorders. This chart reflects market expectations for its clinical development pipeline. Future high profitability will confirm the breakthrough nature of its drugs and their demand.
Market marginality as a whole
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders, particularly epilepsy. Its value lies in the potential of its drugs in development. This graph of total market returns shows the current situation, while Xenon investors look to the future, awaiting clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders, particularly epilepsy. The growth of its scientific and clinical teams, visible in the graph, directly indicates progress in key research programs and progress toward potential commercialization.
Share of the company's employees Xenon Pharmaceuticals within the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for neurological disorders, particularly epilepsy. This chart shows the concentration of scientific talent. It demonstrates the proportion of leading neuroscientists and clinicians working on innovative anticonvulsant drugs that are part of this company.
Number of employees in the market segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders, particularly epilepsy. This chart illustrates employment in neuroscience. The growing number of scientists in this field indicates breakthroughs in our understanding of brain function and increased investment in the discovery of new treatments, which is important to Xenon.
Number of employees in the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders such as epilepsy. The growth of its team of scientists and clinicians reflects advances in brain and nervous system research. This is a contribution to a knowledge-intensive sector, where every new job brings the development of life-saving medicines closer.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals is a biotech company specializing in the treatment of neurological diseases, particularly epilepsy. Their high market capitalization is based on the potential of their drugs in development. This chart is a clear example of how the market values intellectual capital: breakthrough science from a small team of scientists is worth billions of dollars.
%20of%20the%20company%20Xenon%20Pharmaceuticals%20(XENE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Xenon-Pharmaceuticals-XENE&v=1772653983907 "Chart of market capitalization per employee (in thousands of dollars) of the company Xenon Pharmaceuticals (XENE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Xenon is a clinical-stage biotech company specializing in the treatment of epilepsy and other neurological diseases. Its entire market value is based on expectations for its scientific developments. This chart shows the industry average. It helps us understand the significant premium investors are placing on Xenon's R&D team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772653983916 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Xenon Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for neurological diseases such as epilepsy. The company's value is dependent on the success of its research. This chart shows how highly investors value the potential of a small team of scientists to create breakthrough drugs to improve patients' lives.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772653983918 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals is a biotech company specializing in developing treatments for neurological diseases, particularly epilepsy. It's a science-intensive R&D company. At the clinical trial stage, this graph is negative and shows how much the company is investing (burning) per scientist in pursuit of the next neuroscience blockbuster.
%20Chart%20Xenon%20Pharmaceuticals%20(XENE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Xenon-Pharmaceuticals-XENE&v=1772653983934 "Company Profit Per Employee (in thousands of dollars) Chart Xenon Pharmaceuticals (XENE)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Xenon Pharmaceuticals is a clinical-stage biotech company specializing in the treatment of neurological diseases (e.g., epilepsy). This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through cash on R&D (clinical trials).
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772653983948 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Xenon Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological disorders, primarily epilepsy, by targeting ion channels. This R&D is complex. This metric, which illustrates the average profitability per employee in the economy, begs the question: how does the neuroscience sector, where Xenon operates, compare to average profitability?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772653983959 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals is a biotech company specializing in neuroscience. During the drug development stage, this chart is not representative. Zero or low revenue per employee is the norm. However, if one of the drugs is commercially successful, this metric will show a huge leap, reflecting the high value of the company's intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Xenon-Pharmaceuticals-XENE&v=1772653983970 "Sales chart per company employee Xenon Pharmaceuticals (XENE)")
Sales per employee in the market segment - Neuro
Xenon Pharmaceuticals is a biotech company specializing in the treatment of neurological diseases, particularly epilepsy. The company is in clinical development. This chart shows the average revenue per employee in this segment, serving as a productivity benchmark for commercial pharmaceutical companies and context for evaluating XENE's workforce.
Sales per employee for the market as a whole
Xenon Pharmaceuticals is a biotech company specializing in the treatment of neurological diseases (epilepsy). Like other clinical-stage biotechs (CRNX, SRRK), this metric does not yet reflect operational efficiency. The company spends money on R&D. Investors expect successful trials to lead to commercialization and explosive growth in this area.
Short shares by company, segment and market as a whole
Shares shorted by company Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals is a biotech company specializing in developing treatments for neurological diseases, primarily epilepsy. This chart reflects the high risk inherent in biotech companies. Short sellers are betting that their promising drug candidates will fail to prove their safety and efficacy in the critical phases of clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Xenon-Pharmaceuticals-XENE&v=1772653984025 "Short Shares Chart for the Company Xenon Pharmaceuticals (XENE)")
Shares shorted by market segment - Neuro
Xenon Pharmaceuticals is a biotech company specializing in the treatment of neurological disorders, primarily epilepsy. This chart shows pessimism in the neurological pharmaceutical segment. The increase in short positions in the industry may indicate that investors are concerned about the high level of competition in the epilepsy drug market or see risks in clinical trials.
Shares shorted by the overall market
Xenon Pharmaceuticals (XENE) is a clinical-stage biotech company specializing in the treatment of epilepsy and other neurological disorders. This chart measures overall market pessimism. When investors are fearful, they exit speculative biotechs en masse that lack profitability. XENE shares may fall along with the market due to the general "risk-off" sentiment, not due to problems in their development pipeline.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals, which develops drugs to treat neurological diseases (epilepsy), is a volatile biotech stock. This chart can surge above 70 on positive news about clinical trials, but it's also at risk of a correction. A drop below 30 often reflects research setbacks or general investor risk aversion in the sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Xenon-Pharmaceuticals-XENE&v=1772653984075 "RSI 14 indicator chart for the company's stock Xenon Pharmaceuticals (XENE)")
RSI 14 Market Segment - Neuro
Xenon Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurological disorders, primarily epilepsy. This sector is highly dependent on clinical trial data. This chart shows the overall momentum in the neuro biotech segment. It helps distinguish the reaction to XENE's news from general euphoria or industry-wide panic.
RSI 14 for the overall market
Xenon Pharmaceuticals (XENE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XENE (Xenon Pharmaceuticals)
Xenon Pharmaceuticals is a biotech company specializing in developing treatments for neurological diseases, particularly epilepsy. This chart shows the average analyst forecast. Their high target prices reflect the significant potential of the company's drug candidates for treating difficult-to-treat forms of epilepsy and other CNS disorders.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XENE-Xenon-Pharmaceuticals&v=1772653984154 "A chart showing analyst consensus forecasts for the expected stock price. XENE (Xenon Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price XENE (Xenon Pharmaceuticals)
Xenon Pharmaceuticals is a clinical-stage biotech focused on developing new treatments for neurological disorders, primarily epilepsy. This chart reflects analysts' high expectations for their R&D pipeline and clinical trial data. It also reflects the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XENE-Xenon-Pharmaceuticals&v=1772653984238 "A chart showing the difference between the consensus forecast and the actual stock price. XENE (Xenon Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Xenon is a biopharmaceutical company deeply focused on the brain's "ion channels." It is developing new drugs for the treatment of epilepsy. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in the treatment of complex brain diseases are possible.
Analysts' consensus forecast for the overall market share price
Xenon Pharmaceuticals (XENE) is a biotech company specializing in the treatment of neurological diseases, primarily epilepsy. They develop new drugs for patients who are not helped by existing ones. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough neuroscience research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biotech company focused on neuroscience. They are using their expertise in ion channels to develop new treatments for epilepsy and depression. This chart represents pure R&D bets. It likely reflects investors' confidence in the successful clinical trials of their leading epilepsy drugs, rather than revenue.
AKIMA Market Segment Index - Neuro
Xenon Pharma is a clinical-stage biotech focused on neuroscience; the company is developing innovative drugs for the treatment of epilepsy (a competitor of Jazz). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Xenon's niche (epilepsy) R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Xenon is a clinical-stage biotech company focused on neuroscience. It's developing drugs to treat epilepsy. This is a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding companies like Xenon.
